A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

NCT03817658 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

725

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: SHR-1210
DRUG: Placebo

Sponsor

The First Affiliated Hospital of Zhengzhou University

Collaborators

[object Object]